These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet; 1992 Mar 28; 339(8796):753-70. PubMed ID: 1347801 [Abstract] [Full Text] [Related]
5. Haemorrhagic aspects of thrombolytic therapy. Samama M. Eur Heart J; 1990 Aug 28; 11 Suppl F():15-8. PubMed ID: 2121488 [No Abstract] [Full Text] [Related]
6. Which thrombolytic agent should one choose? Topol EJ. Prog Cardiovasc Dis; 1991 Aug 28; 34(3):165-78. PubMed ID: 1947122 [No Abstract] [Full Text] [Related]
7. Management of myocardial infarction in the community: a new RCGP study. Kay C. Br J Gen Pract; 1991 Mar 28; 41(344):89-90. PubMed ID: 1903264 [No Abstract] [Full Text] [Related]
8. What you should know about thrombolytic therapy for acute MI. Aragon D, Martin M. Am J Nurs; 1993 Sep 28; 93(9):24-31; quiz 33. PubMed ID: 8213959 [No Abstract] [Full Text] [Related]
17. Fibrinolysis for myocardial infarction: the ISIS-2 and asset trials. Drug Ther Bull; 1989 Oct 16; 27(21):81-2. PubMed ID: 2519134 [No Abstract] [Full Text] [Related]